12:00 AM
 | 
Jan 18, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PORxin: Phase IIb data

Top-line data from the double-blind, Canadian Phase IIb TRIUMPH trial in 73 patients showed that PRX302 met the primary endpoint of a significant improvement in IPSS from baseline to day 90 vs. placebo (9.1 vs. 5.8 points, p=0.0238). In a subgroup of...

Read the full 186 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >